Clinical Feautures APS/X
Jun 12, 2025, 09:14
Understanding Antiphospholipid Syndrome (APS): Diagnosis and Clinical Clues Every Clinician Should Know-by APS Foundation of America
The APS Foundation of America has pinned a critical update on their X page, shedding light on the diagnostic criteria and clinical features of Antiphospholipid Syndrome (APS)—a serious autoimmune condition that significantly increases the risk of blood clots, pregnancy complications, and organ damage.
Diagnosis of APS requires both clinical manifestations and positive laboratory findings. The most commonly used tests include:
Anticardiolipin antibodies (IgG, IgM, IgA)
Lupus anticoagulant testing (e.g., dRVVT, aPTT, mixing studies)
Anti-β2 glycoprotein I antibodies (IgG, IgM, IgA)
These tests help differentiate APS from other causes of coagulopathy and are essential for accurate classification and management.
Clinical features may include:
Recurrent venous or arterial thrombosis
Recurrent miscarriages or severe pregnancy complications (e.g., pre-eclampsia)
Thrombocytopenia
Stroke or transient ischemic attacks
Livedo reticularis, skin ulcers, and — in severe cases — Catastrophic APS
APS is a multisystemic disorder that requires high clinical suspicion, especially in young patients with unexplained thrombotic events or adverse pregnancy outcomes.
See full details and expert perspectives now on Hemostasis Today.
American Society of Hematology
Anticardiolipin Antibodies
Antiphospholipid Syndrome
APS Awareness
APS Diagnosis
APSFA
Autoimmune Coagulopathy
Catastrophic APS
Hematology
Hemostasis Today
International Society on Thrombosis and Haemostasis (ISTH)
Lupus Anticoagulant
Pregnancy Loss
Th APS Foundation of America
thrombosis
β2 Glycoprotein I
-
Sep 18, 2025, 06:50Fetal Hereditary TTP Featured in NEJM – Senior Author Nishant Rajendra Tiwari
-
Sep 17, 2025, 10:54Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
-
Sep 17, 2025, 08:16Superficial Vein Thrombosis Management: John Fanikos Shares Latest Review
-
Sep 17, 2025, 07:00Maha Othman - ''BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!''
-
Sep 16, 2025, 11:17Glenn Pierce: WHO Issues a Biannual Essential Medicines List
-
Sep 18, 2025, 07:00Rishabh Singh on NEJM Letter: FVIII Aurora Mutation Shows Increased Activity and Reduced APC Response
-
Sep 18, 2025, 02:25Flora Peyvandi Highlights 'Inflammatory Memory of Stem Cells' – New Insights for Hematologic Diseases
-
Sep 17, 2025, 16:32Endovascular Today: Dr. Eric Secemsky Analyzes Impact of Paclitaxel Pause on Peripheral Artery Disease Care
-
Sep 17, 2025, 16:28Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
-
Sep 17, 2025, 16:19Todd Villines: Coronary Artery Disease - A BIG Movement to Change
-
Sep 16, 2025, 14:59A New Era in Antiplatelet Therapy for CABG?
-
Sep 16, 2025, 07:44Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
-
Sep 16, 2025, 02:44Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 18, 2025, 06:34'A New Era in Mechanical Thrombectomy?' – Sripal Bangalore Highlights SYMPHONY-PE IDE Study
-
Sep 17, 2025, 10:49Living with Glanzmann Thrombasthenia․ Eliza VanZweden’s Story of Resilience and Advocacy
-
Sep 17, 2025, 10:22Abdul Mannan: Turning Medical Podcasts into Active Learning with Structured Tools
-
Sep 17, 2025, 09:43Global Blood Supply Under Threat: David McIntosh Calls for Action to Support Transfusion Services
-
Sep 17, 2025, 09:08Coronary Arteries, Pericardial Cavity, and the Hidden Danger of Cardiac Tamponade During PCI-By Ahmed Ata
Sep 18, 2025, 06:50
Sep 17, 2025, 16:19
Sep 17, 2025, 10:36